HilleVax’s (HLVX) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of HilleVax (NASDAQ:HLVX) in a report released on Monday morning,Benzinga reports. They currently have a $2.00 price objective on the stock.

HilleVax Price Performance

Shares of NASDAQ HLVX opened at $1.45 on Monday. The stock has a market capitalization of $72.22 million, a PE ratio of -0.47 and a beta of 0.76. HilleVax has a one year low of $1.41 and a one year high of $16.66. The business’s fifty day moving average price is $1.81 and its 200-day moving average price is $1.86.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings data on Friday, March 28th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). As a group, equities analysts expect that HilleVax will post -2.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of HLVX. Barclays PLC raised its holdings in HilleVax by 14.1% during the 4th quarter. Barclays PLC now owns 47,946 shares of the company’s stock valued at $100,000 after acquiring an additional 5,913 shares during the period. SG Americas Securities LLC grew its position in shares of HilleVax by 61.6% in the fourth quarter. SG Americas Securities LLC now owns 18,145 shares of the company’s stock valued at $38,000 after purchasing an additional 6,916 shares in the last quarter. Northern Trust Corp grew its position in shares of HilleVax by 2.8% in the fourth quarter. Northern Trust Corp now owns 249,610 shares of the company’s stock valued at $517,000 after purchasing an additional 6,916 shares in the last quarter. Ieq Capital LLC raised its stake in shares of HilleVax by 71.1% during the 4th quarter. Ieq Capital LLC now owns 22,495 shares of the company’s stock valued at $47,000 after purchasing an additional 9,344 shares during the period. Finally, Bank of Montreal Can lifted its holdings in HilleVax by 47.1% during the 4th quarter. Bank of Montreal Can now owns 35,763 shares of the company’s stock worth $74,000 after purchasing an additional 11,459 shares in the last quarter. 86.42% of the stock is owned by institutional investors.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.